Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia

Author:            

Publisher: Spandidos Publications

ISSN: 1021-335X

Source: Oncology Reports, Vol.27, Iss.2, 2012-01, pp. : 461-466

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract